Glucagon-Like Peptide I (GLP-1) is a naturally occurring peptide hormone secreted by the intestinal L cells in response to food intake. GLP-1(7-36), also known as GLP-1 Amide Fragment 7-36 human, is a biologically active fragment of GLP-1 that has gained attention for its potential therapeutic properties in the treatment of type 2 diabetes and obesity. GLP-1(7-36) works by stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying.
Chemical name:
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Molecular formula:
C149H226N40O45
Formula weight:
3355.29 g/mol
CAS No:
107444-51-9
Top ten keywords from Google and Synonyms:
Health benefits of this product:
GLP-1(7-36) has shown potential health benefits in the treatment of type 2 diabetes and obesity. Studies have found that GLP-1(7-36) stimulates insulin secretion, suppresses glucagon secretion, and delays gastric emptying, resulting in improved glucose regulation and weight loss. Additionally, GLP-1(7-36) exhibits neuroprotective effects, potentially reducing the risk of neurodegenerative diseases.
Potential effects:
GLP-1(7-36) has several potential effects on the body. One of the primary mechanisms is through its role in glucose regulation and weight loss. GLP-1(7-36) stimulates insulin secretion, suppresses glucagon secretion, and delays gastric emptying, resulting in improved glucose regulation and weight loss. Additionally, GLP-1(7-36) exhibits neuroprotective effects, potentially reducing the risk of neurodegenerative diseases.
Product mechanism:
GLP-1(7-36) works by stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying. The peptide binds to the GLP-1 receptor, activating several signaling pathways involved in glucose regulation and weight loss. GLP-1(7-36) also exhibits neuroprotective effects by promoting the survival of neurons and reducing oxidative stress.
Safety:
GLP-1(7-36) is generally considered safe and well-tolerated. However, GLP-1-based therapies have been associated with an increased risk of pancreatitis and pancreatic cancer. Therefore, caution should be taken when using GLP-1(7-36)-based therapies, particularly in patients with a history of pancreatitis or pancreatic cancer.
Side effects:
Some common side effects of GLP-1(7-36)-based therapies include nausea, vomiting, and diarrhea. Additionally, GLP-1-based therapies have been associated with an increased risk of hypoglycemia, particularly when used in combination with other glucose-lowering agents.
Dosing information:
The dosing of GLP-1(7-36)-based therapies varies depending on the specific product and patient characteristics. Typically, GLP-1(7-36)-based therapies are administered subcutaneously once daily or once weekly.
Conclusion:
GLP-1(7-36) is a biologically active fragment of GLP-1 that has gained attention for its potential therapeutic properties in the treatment of type 2 diabetes and obesity. The peptide works by stimulating insulin secretion, suppressing glucagon secretion, and delaying gastric emptying. While GLP-1(7-36) shows promise as a therapeutic agent, caution should be taken when using GLP-1-based therapies due to the risk of pancreatitis and pancreatic cancer. Nonetheless, GLP-1(7-36) remains a promising candidate for the development of novel treatments for type 2 diabetes and obesity
